Drug interactions
Caplacizumab + Ticagrelor
Severity: Major
Caplacizumab and Ticagrelor: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Caplacizumab blocks von Willebrand factor-mediated platelet adhesion, and ticagrelor inhibits platelet aggregation via P2Y12. Together they increase the risk of bleeding, including serious hemorrhage.
What this interaction means in plain words
Caplacizumab and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Caplacizumab belongs to Cardiovascular; Ticagrelor belongs to Cardiovascular.
Why it happens
Additive impairment of primary hemostasis through different antiplatelet pathways.
What to do
Avoid combining where possible; if antiplatelet therapy is essential, monitor closely for bleeding and hemoglobin. Consider holding ticagrelor around invasive procedures.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Caplacizumab and Ticagrelor, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ticagrelor
- Itraconazole + Ticagrelor Contraindicated
- Ketoconazole + Ticagrelor Contraindicated
- Levoketoconazole + Ticagrelor Contraindicated
- Abciximab + Ticagrelor Major
- Abrocitinib + Ticagrelor Major
- Acalabrutinib + Ticagrelor Major
Other interactions of Caplacizumab
Frequently asked questions
Can I take Caplacizumab with Ticagrelor?
MediHelp rates the interaction as major. Caplacizumab and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Caplacizumab blocks von Willebrand factor-mediated platelet adhesion, and ticagrelor inhibits platelet aggregation via P2Y12. Together they increase the risk of bleeding, including serious hemorrhage.
How serious is the interaction between Caplacizumab and Ticagrelor?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible; if antiplatelet therapy is essential, monitor closely for bleeding and hemoglobin. Consider holding ticagrelor around invasive procedures.
What other medicines interact with Ticagrelor?
MediHelp also lists interactions of Ticagrelor with, for example, Itraconazole, Ketoconazole, Levoketoconazole. The full list is on the Ticagrelor page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
